---
title: "Psyence Labs Discloses Investment in PSYENCE BIOMEDICAL LTD. with 30.05% Stake"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/288586595.md"
description: "Psyence Labs disclosed a 30.05% stake in PSYENCE BIOMEDICAL LTD. via a share-for-share exchange valued at $5 million, filed on June 3, 2026. Psyence Labs holds sole voting and dispositive power over 1,146,159 shares. The BVI-based company, focused on psychedelic pharmaceutical ingredients, intends to hold the investment for potential future acquisition or disposal but has no immediate plans for corporate changes."
datetime: "2026-06-03T13:36:00.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/288586595.md)
  - [en](https://longbridge.com/en/news/288586595.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/288586595.md)
generator: "portal-rs"
---

# Psyence Labs Discloses Investment in PSYENCE BIOMEDICAL LTD. with 30.05% Stake

Psyence Labs Ltd. disclosed a 30.05% stake in PSYENCE BIOMEDICAL LTD.'s common shares. The stake stems from a share‑for‑share exchange completed on Feb. 25, 2026, and was reported in a Schedule 13D filed on Jun. 03, 2026. The exchange valued Psyence Labs’ contribution at $5 million and gave it sole voting and dispositive power over 1,146,159 shares.

**Investor Intent**

Psyence Labs holds the shares for investment and will keep reviewing the position. It may "acquire additional Common Shares" or "dispose of any or all of the Securities," and could use hedging, while it currently has no specific plans for corporate changes.

**Investor's Background**

Psyence Labs Ltd. is a British Virgin Islands company that cultivates, manufactures, and supplies nature-derived psychedelic active pharmaceutical ingredients, including pharmaceutical-grade ibogaine and psilocybin. The company focuses on regulated research and medical markets for psychedelic compounds. It invests strategically in related ventures to support development and commercialization of these therapies.

Original SEC Filing: PSYENCE BIOMEDICAL LTD. \[ PBM \] - SCHEDULE 13D - Jun. 03, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [PBM.US](https://longbridge.com/en/quote/PBM.US.md)
- [PBMWW.US](https://longbridge.com/en/quote/PBMWW.US.md)

## Related News & Research

- [TechDigital Labs Expands Local SEO Services to Help Businesses Strengthen Regional Visibility](https://longbridge.com/en/news/298061940.md)
- [Why the AI boom has become an election problem](https://longbridge.com/en/news/297766132.md)
- [Proto Labs, Inc. $PRLB Shares Purchased by Algert Global LLC](https://longbridge.com/en/news/297395843.md)
- [$100 Invested In Darling Ingredients 10 Years Ago Would Be Worth This Much Today](https://longbridge.com/en/news/297667597.md)
- [Exascale Labs Holdings Announced Transfer or Voluntary Withdrawal of Listing](https://longbridge.com/en/news/297805044.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**